It's the NCCN guidelines um in T-cell lymphoma certainly uses um and highlights drugs and, and combinations that have been specifically FDA approved for peripheral T cell lymphomas. Those include um brintuximabiddotin, um, Romosin, which was uh previously at least FDA approved based on a pivotal phase 2 study. Uh bilinostat, another histonediacetylase inhibitor, uh Prilatrexate and anti-folate agent, but then also includes other agents, um, that have shown to be efficacious. And, and, um, the way the NCCN guidelines work is that um there are certainly um trials that have led to an overall survival benefit that then get a category one recommendation. But in, in the other um drugs that are that don't meet that um bar, um, the NCCN panel, which consists of um experts from the representative NCCN member institutions, will vote on whether they would commonly use um certain agents or combinations in their clinical practice. And based on the percentage of the uh panel, the academic expert panel that utilizes these agents in their practice based on published and presented literature, that, um, there is a chance that some of those other agents also get incorporated within the NCCN guidelines. So as a result of that and the strong data from uh Primo, which is one of The largest studies in in T cell lymphoma that has been done showing a, you know, of almost 50% response rate across the board and a nearly over 60% response rate in AITL. Duvaliid was incorporated as a potential option for relapse from refractory peripheral T cell lymphomas, including TFH phenotype lymphomas. Um, within the NCCN guidelines. What that means for providers is that um they can um use that information to apply for approval, insurance approval for um Dubili for their patients. Um, similarly, laidomide has been incorporated, um, the combination of Dubilic plus Roadsin had been incorporated, um, roxalitinib has been incorporated within the NCCN guidelines as these are agents that are used by experts in relapse refractory patients based on um. Based on um prospective clinical trials that have been presented and published in peripheral T cell lymphoma.
Presenter
